CA2859156C - Treatment of type i and type ii diabetes - Google Patents
Treatment of type i and type ii diabetes Download PDFInfo
- Publication number
- CA2859156C CA2859156C CA2859156A CA2859156A CA2859156C CA 2859156 C CA2859156 C CA 2859156C CA 2859156 A CA2859156 A CA 2859156A CA 2859156 A CA2859156 A CA 2859156A CA 2859156 C CA2859156 C CA 2859156C
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- compound
- administration
- compounds
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569496P | 2011-12-12 | 2011-12-12 | |
| US61/569,496 | 2011-12-12 | ||
| PCT/US2012/069072 WO2013090319A2 (en) | 2011-12-12 | 2012-12-12 | Treatment of type i and type ii diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2859156A1 CA2859156A1 (en) | 2013-06-20 |
| CA2859156C true CA2859156C (en) | 2020-10-06 |
Family
ID=48613352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859156A Active CA2859156C (en) | 2011-12-12 | 2012-12-12 | Treatment of type i and type ii diabetes |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150190396A1 (OSRAM) |
| EP (1) | EP2790704B1 (OSRAM) |
| JP (1) | JP6152387B2 (OSRAM) |
| KR (1) | KR102069395B1 (OSRAM) |
| CN (2) | CN104271140B (OSRAM) |
| AU (2) | AU2012352480A1 (OSRAM) |
| BR (1) | BR112014014289A8 (OSRAM) |
| CA (1) | CA2859156C (OSRAM) |
| IL (1) | IL233004B (OSRAM) |
| MX (1) | MX359171B (OSRAM) |
| RU (1) | RU2646475C2 (OSRAM) |
| SG (2) | SG11201403207WA (OSRAM) |
| WO (1) | WO2013090319A2 (OSRAM) |
| ZA (1) | ZA201404738B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10863264B2 (en) | 2017-01-23 | 2020-12-08 | David Sampson | Vibration inducing tactile apparatus |
| JP7033662B2 (ja) * | 2018-01-11 | 2022-03-10 | バクワン ファーマスティカル カンパニー リミテッド | 大規模なトリミドンの調製方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922345A (en) | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20070025953A1 (en) * | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| EP1924262B1 (en) * | 2005-08-22 | 2011-11-16 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| RU2316339C1 (ru) * | 2006-09-13 | 2008-02-10 | Общество С Ограниченной Ответственностью "Концерн О3" | Способ получения препарата инсулина для перорального применения |
| JP2010518860A (ja) * | 2007-02-20 | 2010-06-03 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Ｌｙｎキナーゼの活性化剤の同定方法 |
| CA2693809A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating irs-1 and akt |
| ES2530223T3 (es) * | 2008-12-12 | 2015-02-27 | Poxel S.A.S. | Combinación de insulina con derivados de triazina y su uso para tratar la diabetes |
| US20130158055A1 (en) * | 2010-05-28 | 2013-06-20 | Andrew G. Reaume | Prevention Of Pancreatic Beta Cell Degeneration |
| AU2018250795B2 (en) * | 2017-04-10 | 2022-02-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatment of adipocytes |
-
2012
- 2012-12-12 SG SG11201403207WA patent/SG11201403207WA/en unknown
- 2012-12-12 KR KR1020147019062A patent/KR102069395B1/ko active Active
- 2012-12-12 WO PCT/US2012/069072 patent/WO2013090319A2/en not_active Ceased
- 2012-12-12 RU RU2014128528A patent/RU2646475C2/ru active
- 2012-12-12 BR BR112014014289A patent/BR112014014289A8/pt not_active Application Discontinuation
- 2012-12-12 CN CN201280069531.5A patent/CN104271140B/zh active Active
- 2012-12-12 SG SG10201604828QA patent/SG10201604828QA/en unknown
- 2012-12-12 US US14/364,792 patent/US20150190396A1/en not_active Abandoned
- 2012-12-12 JP JP2014547360A patent/JP6152387B2/ja active Active
- 2012-12-12 EP EP12857229.4A patent/EP2790704B1/en active Active
- 2012-12-12 MX MX2014006990A patent/MX359171B/es active IP Right Grant
- 2012-12-12 CN CN201610988112.1A patent/CN107007608B/zh active Active
- 2012-12-12 CA CA2859156A patent/CA2859156C/en active Active
- 2012-12-12 AU AU2012352480A patent/AU2012352480A1/en not_active Abandoned
-
2014
- 2014-06-08 IL IL233004A patent/IL233004B/en unknown
- 2014-06-26 ZA ZA2014/04738A patent/ZA201404738B/en unknown
-
2017
- 2017-07-07 AU AU2017204652A patent/AU2017204652B2/en active Active
-
2020
- 2020-01-08 US US16/737,200 patent/US20200215068A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6152387B2 (ja) | 2017-06-21 |
| RU2014128528A (ru) | 2016-02-10 |
| EP2790704A4 (en) | 2015-09-02 |
| RU2646475C2 (ru) | 2018-03-05 |
| SG10201604828QA (en) | 2016-07-28 |
| KR102069395B1 (ko) | 2020-01-22 |
| SG11201403207WA (en) | 2014-09-26 |
| KR20140107416A (ko) | 2014-09-04 |
| BR112014014289A2 (pt) | 2017-06-13 |
| CN104271140B (zh) | 2016-11-23 |
| AU2012352480A1 (en) | 2014-07-17 |
| IL233004B (en) | 2020-01-30 |
| WO2013090319A3 (en) | 2014-12-04 |
| JP2015513310A (ja) | 2015-05-07 |
| CN107007608A (zh) | 2017-08-04 |
| CA2859156A1 (en) | 2013-06-20 |
| EP2790704A2 (en) | 2014-10-22 |
| AU2017204652A1 (en) | 2017-07-27 |
| CN107007608B (zh) | 2021-04-23 |
| IL233004A0 (en) | 2014-07-31 |
| HK1202819A1 (en) | 2015-10-09 |
| ZA201404738B (en) | 2016-10-26 |
| NZ626495A (en) | 2016-03-31 |
| CN104271140A (zh) | 2015-01-07 |
| EP2790704B1 (en) | 2019-04-03 |
| BR112014014289A8 (pt) | 2017-06-13 |
| US20200215068A1 (en) | 2020-07-09 |
| MX359171B (es) | 2018-09-18 |
| AU2017204652B2 (en) | 2018-08-16 |
| US20150190396A1 (en) | 2015-07-09 |
| MX2014006990A (es) | 2015-02-05 |
| WO2013090319A2 (en) | 2013-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12064432B2 (en) | Treatment of adipocytes | |
| US20200215068A1 (en) | Treatment of type i and type ii diabetes | |
| WO2022026645A1 (en) | Treatment of acute respiratory distress syndrome (ards) | |
| CA3088178A1 (en) | Treatment of liver diseases | |
| JPH10507446A (ja) | ビス−２−アミノピリジン類、その製造方法及び寄生虫感染を制御するためのその用途 | |
| Reaume et al. | Treatment of adipocytes | |
| HK1202819B (en) | Treatment of type i diabetes | |
| NZ626495B2 (en) | Treatment of type i and type ii diabetes | |
| BR112019021140B1 (pt) | Composição, e, uso de um ativador de lyn cinase e de um agonista de trpm8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241126 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241126 |